BACKGROUND To investigate the one-year visual and anatomical outcomes of combination therapy with intravitreal aflibercept (IVA) and photodynamic therapy (PDT) for treating polypoidal choroidal vasculopathy (PCV). METHODS This was a retrospective case-series study, including 30 eyes from 30 patients with treatment-naïve PCV treated by combination therapy with IVA and PDT. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), complete polyp regression rate, and dry macula rate were recorded every 3 months during 12-month follow-up. Clinical factors associated with final visual outcome and retreatment were investigated. RESULTS The mean LogMAR BCVA was significantly improved from 0.73 ± 0.65 at baseline to 0.51 ± 0.60 (p = 0.01), and the mean CRT was also significantly improved from 339 ± 96 μm at baseline to 244 ± 43 μm at 12-month follow-up (p <  0.001). Complete regression of polypoidal lesions was 76.7%, and dry macula rate was 100% at 12 months. Better final BCVA was associated with younger age and better baseline BCVA (p = 0.02 and p <  0 001). The patients without complete polyp regression at 3-month follow-up were associated with retreatment (p = 0.03). CONCLUSION In this study, combination therapy with IVA and PDT had significant visual and anatomical improvements to PCV patients during one-year follow-up. Better baseline BCVA and younger age were found to be associated with better visual outcome.

中文翻译：

---

玻璃体腔注射阿柏西普和光动力疗法联合治疗息肉样脉络膜血管病的一年结局。

背景技术探讨玻璃体腔内使用阿柏西普（IVA）和光动力疗法（PDT）联合治疗息肉样脉络膜血管病（PCV）的一年视觉和解剖学结果。方法这是一项回顾性病例系列研究，包括30例接受过IVA和PDT联合治疗的初治PCV患者的30只眼。在12个月的随访期间，每3个月记录一次最佳矫正视力（BCVA），视网膜中央厚度（CRT），息肉完全消退率和干黄斑率。研究与最终视觉结果和再治疗相关的临床因素。结果LogMAR BCVA的平均值从基线的0.73±0.65显着提高到0.51±0.60（p = 0.01），平均CRT也从基线时的339±96μm显着提高到12个月随访时的244±43μm（p <0.001）。12个月时，息肉样病变的完全消退率为76.7％，干黄斑率为100％。最终的BCVA越好，年龄越小，基线BCVA越好（p = 0.02，p <0 001）。在3个月的随访中没有完全息肉消退的患者与再治疗相关（p = 0.03）。结论在这项研究中，在一年的随访期间，IVA和PDT的联合治疗对PCV患者具有明显的视觉和解剖学改善。发现更好的基线BCVA和年龄较小与更好的视觉效果有关。最终的BCVA越好，年龄越小，基线BCVA越好（p = 0.02，p <0 001）。在3个月的随访中没有完全息肉消退的患者与再治疗相关（p = 0.03）。结论在这项研究中，在一年的随访期间，IVA和PDT的联合治疗对PCV患者具有明显的视觉和解剖学改善。发现更好的基线BCVA和年龄较小与更好的视觉效果有关。最终的BCVA越好，年龄越小，基线BCVA越好（p = 0.02，p <0 001）。在3个月的随访中没有完全息肉消退的患者与复治有关（p = 0.03）。结论在这项研究中，在一年的随访期间，IVA和PDT的联合治疗对PCV患者具有明显的视觉和解剖学改善。发现更好的基线BCVA和年龄较小与更好的视觉效果有关。